Reference priceJPY ¥770.00Original source price: INR 440.00. Converted estimates are available by currency selection.
| Brand | Yesintek |
|---|---|
| Manufacturer | Biocon Biologics Ltd（BBL） |
| Prescription required | Yes |
Yesintek 90mg/mlSyringe,1per x 1(ustekinumab-kfce)
ustekinumab-kfce
Description
Yesintek 90mg/mlSyringe,1per x 1(ustekinumab-kfce) is a medicine catalog record in the MediPriceHub database. Active ingredient: ustekinumab-kfce. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Biocon Biologics Ltd（BBL）. Therapeutic category: Medicine Library > Dermatology Medicines > Drugs for psoriasis. Pack information: 90 /, 1 x 1. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Ustekinumab-aekn is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. active psoriatic arthritis (PsA) . moderately to severely active Crohn’s disease (CD). moderately to severely active ulcerative colitis. Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO) , who are candidates for phototherapy or systemic therapy. active psoriatic arthritis (PsA) . 1.1 Plaque Psoriasis (PsO) Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) Ustekinumab-aekn is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn’s Disease (CD) Ustekinumab-aekn is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease. 1.4 Ulcerative Colitis Ustekinumab-aekn is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.How to Use
Use ustekinumab-kfce under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: ustekinumab-kfce. Pack size: 90 /, 1 x 1. Pack unit: tube. Manufacturer: Biocon Biologics Ltd（BBL）. Origin country: United States. Source category: Medicine Library > Dermatology Medicines > Drugs for psoriasis. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Possible adverse effects vary by active ingredient, dose, route, treatment duration, and patient condition. Common issues may include gastrointestinal symptoms, headache, dizziness, fatigue, rash, allergic reactions, or abnormal laboratory tests. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.この情報は参考情報です。医薬品を使用する前に医療専門家へご相談ください。